Neotec is a highly competitive programme that aims to foster technology and innovation for the development of companies based in Spain. In the 2022 call, the programme awarded grants to 135 projects. In this regard, it is significant that the Telara Pharma research project was among the top projects since it highlights the company’s solid business model, science and the importance to explore new applications of cilastatin into other areas related with neurodegenerative and inflammatory disorders.
The grant entitled “DEVELOPMENT OF A NEW AGENT FOR PROTECTION AGAINST APOPTOSIS, CILASTATIN, AIMED AT THE TREATMENT OF NEURODEGENERATIVE PROCESSES” will allow the company to continue the research and development on cilastatin for neurodegenerative disorders having apoptosis as a key factor and will generate proof of concept data on several therapeutic indications.
The company will also reinforce its R&D team, hiring a senior scientist with a strong background in physiology and molecular biology.
Telara Pharma is a global leader in repurposing the drug cilastatin to make therapies for severe inflammatory disorders like Acute Kidney Injury (AKI).
The founding team of TELARA has spent years studying toxic and non-toxic aggressions suffered by the kidneys with the aim of modelling the main clinical causes that produce it and trying to advance in the field of prevention and treatment of AKI. The company arises out of the pioneering work on nephroprotection carried out with cilastatin by Dr. Alberto Tejedor, with the intention of fulfilling one of his dreams, to cover a medical need that is not currently covered.